Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VAL-339851 in Healthy Subjects
Sponsor: ModernaTX, Inc.
A PHASE1 clinical study on Influenza, this trial is completed. The trial is conducted by ModernaTX, Inc. and has accumulated 11 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
-
May 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — May 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Dec 2017 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .